别名 1-acylglycerol-3-phosphate O-acyltransferase PNPLA3、Acylglycerol transacylase、Adiponutrin + [13] |
简介 Specifically catalyzes coenzyme A (CoA)-dependent acylation of 1-acyl-sn-glycerol 3-phosphate (2-lysophosphatidic acid/LPA) to generate phosphatidic acid (PA), an important metabolic intermediate and precursor for both triglycerides and glycerophospholipids. Does not esterify other lysophospholipids. Acyl donors are long chain (at least C16) fatty acyl-CoAs: arachidonoyl-CoA, linoleoyl-CoA, oleoyl-CoA and at a lesser extent palmitoyl-CoA (PubMed:22560221). Additionally possesses low triacylglycerol lipase and CoA-independent acylglycerol transacylase activities and thus may play a role in acyl-chain remodeling of triglycerides (PubMed:15364929, PubMed:20034933, PubMed:22560221). In vitro may express hydrolytic activity against glycerolipids triacylglycerol, diacylglycerol and monoacylglycerol, with a strong preference for oleic acid as the acyl moiety (PubMed:21878620). However, the triacylglycerol hydrolase activity is controversial and may be very low (PubMed:22560221). Possesses phospholipase A2 activity (PubMed:15364929). |
靶点 |
作用机制 PNPLA3抑制剂 |
在研机构 |
非在研适应症- |
最高研发阶段临床2期 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
靶点 |
作用机制 PNPLA3调节剂 [+1] |
在研适应症 |
非在研适应症- |
最高研发阶段临床1期 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
靶点 |
作用机制 PNPLA3调节剂 |
在研机构 |
原研机构 |
在研适应症 |
非在研适应症 |
最高研发阶段临床1期 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
开始日期2024-04-15 |
开始日期2023-09-20 |
申办/合作机构 AstraZeneca AB [+2] |
开始日期2023-08-03 |
申办/合作机构 |